tiprankstipranks
Trending News
More News >
Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Advertisement

Aptevo Therapeutics (APVO) Price & Analysis

Compare
603 Followers

APVO Stock Chart & Stats


Aptevo Therapeutics News

APVO FAQ

What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $1.72 and its highest was $381.75 in the past 12 months.
    What is Aptevo Therapeutics Inc’s market cap?
    Aptevo Therapeutics Inc’s market cap is $6.54M.
      When is Aptevo Therapeutics Inc’s upcoming earnings report date?
      Aptevo Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 76 days.
        How were Aptevo Therapeutics Inc’s earnings last quarter?
        Aptevo Therapeutics Inc released its earnings results on Aug 11, 2025. The company reported -$8.4 earnings per share for the quarter, beating the consensus estimate of -$83.2 by $74.8.
          Is Aptevo Therapeutics Inc overvalued?
          According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Aptevo Therapeutics Inc pay dividends?
            Aptevo Therapeutics Inc does not currently pay dividends.
            What is Aptevo Therapeutics Inc’s EPS estimate?
            Aptevo Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Aptevo Therapeutics Inc have?
            Aptevo Therapeutics Inc has 3,287,918 shares outstanding.
              What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
              Aptevo Therapeutics Inc reported an EPS of -$8.4 in its last earnings report, beating expectations of -$83.2. Following the earnings report the stock price went down -4.867%.
                Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
                Currently, no hedge funds are holding shares in APVO

                Company Description

                Aptevo Therapeutics Inc

                Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

                Aptevo Therapeutics (APVO) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                VivoSim Labs
                Enveric Biosciences
                Ensysce Biosciences
                Revelation Biosciences
                Tao Synergies

                Ownership Overview

                <0.01%0.02%0.03%99.98%
                <0.01% Insiders
                0.03% Other Institutional Investors
                99.98% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis